Trump to Release 80,000 Pages on JFK Assassination 

Newly-elected President Kennedy posed for first pictures at his White House desk, Jan. 21, 1961, before plunging into a busy round of conferences. (AP)
Newly-elected President Kennedy posed for first pictures at his White House desk, Jan. 21, 1961, before plunging into a busy round of conferences. (AP)
TT

Trump to Release 80,000 Pages on JFK Assassination 

Newly-elected President Kennedy posed for first pictures at his White House desk, Jan. 21, 1961, before plunging into a busy round of conferences. (AP)
Newly-elected President Kennedy posed for first pictures at his White House desk, Jan. 21, 1961, before plunging into a busy round of conferences. (AP)

President Donald Trump plans to release about 80,000 pages of material related to the 1963 assassination of President John F. Kennedy on Tuesday, seeking to honor his campaign promise to provide more transparency about the shock event in Texas.

"It's a lot of stuff, and you'll make your own determination," Trump told reporters about the pages on Monday. Trump signed an order shortly after taking office in January related to the release, prompting the US Federal Bureau of Investigation to find thousands of new documents related to the Kennedy assassination in Dallas.

Kennedy's murder has been attributed to a sole gunman, Lee Harvey Oswald. The Justice Department and other federal government bodies reaffirmed that conclusion in the intervening decades. But polls show many Americans believe his death was a result of a conspiracy.

Experts doubt the new trove of information will change the underlying facts of the case, that Lee Harvey Oswald opened fire at Kennedy from a window at a schoolbook deposit warehouse as the presidential motorcade passed by on a Dallas highway.

"People expecting big things are almost certain to be disappointed," said Larry Sabato, the director of the Center for Politics at the University of Virginia, who authored a book about the assassination.

He said some of the pages could simply be the release of previously published material that had a few words redacted.

Trump has also promised to release documents on the assassinations of civil rights leader Martin Luther King, Jr. and Senator Robert Kennedy, both of whom were killed in 1968.

Trump has allowed more time to come up with a plan for those releases.

Trump's secretary of Health and Human Services, Robert F. Kennedy Jr., the son of Robert Kennedy and nephew of John F. Kennedy, has said he believes the Central Intelligence Agency was involved in his uncle's death, an allegation the agency has described as baseless.

Kennedy Jr. has also said he believes his father was killed by multiple gunmen, an assertion that contradicted official accounts.

One revelation the documents could contain is that the CIA was more aware of Oswald than it has previously disclosed. Questions have remained about what the CIA knew about Oswald's visits to Mexico City six weeks before the assassination. During that trip, Oswald visited the Soviet embassy.

"People have been waiting for decades for this," Trump said. "It's going to be very interesting."



Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
TT

Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.

The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.